LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1194

Search options

  1. Article: [No title information]

    Scheen, A J

    Revue medicale de Liege

    2023  Volume 78, Issue 1, Page(s) 1–3

    Title translation Éditorial. Le système des soins de santé ébranlé par les crises.
    MeSH term(s) Humans ; Delivery of Health Care
    Language French
    Publishing date 2023-01-12
    Publishing country Belgium
    Document type Editorial
    ZDB-ID 414001-1
    ISSN 0370-629X ; 0035-3663
    ISSN 0370-629X ; 0035-3663
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 597: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Does race/ethnicity influence the impact of new glucose-lowering agents on cardiovascular outcomes?-a comparison between Asian versus White patients.

    Scheen, André J

    Annals of translational medicine

    2023  Volume 10, Issue 24, Page(s) 1418

    Language English
    Publishing date 2023-01-20
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm-2022-54
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation.

    Scheen, André J

    The Lancet regional health. Europe

    2023  Volume 29, Page(s) 100627

    Language English
    Publishing date 2023-03-30
    Publishing country England
    Document type Journal Article
    ISSN 2666-7762
    ISSN (online) 2666-7762
    DOI 10.1016/j.lanepe.2023.100627
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: [No title information]

    Scheen, André J

    Revue medicale suisse

    2023  Volume 19, Issue 838, Page(s) 1483–1484

    Title translation Personnaliser l’approche du diabète de type 2 : chirurgie métabolique et/ou pharmacothérapie.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2 ; Bariatric Surgery
    Language French
    Publishing date 2023-08-23
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.838.1483
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Pragmatic trials, a step forward to assess cardiovascular efficacy of new glucose-lowering agents.

    Scheen, André J

    The lancet. Diabetes & endocrinology

    2023  Volume 11, Issue 9, Page(s) 626–627

    MeSH term(s) Humans ; Glucose ; Hypoglycemic Agents/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Cardiovascular System ; Cardiovascular Diseases/prevention & control
    Chemical Substances Glucose (IY9XDZ35W2) ; Hypoglycemic Agents
    Language English
    Publishing date 2023-07-24
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2213-8595
    ISSN (online) 2213-8595
    DOI 10.1016/S2213-8587(23)00161-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Effets des médicaments antidiabétiques sur la stéatopathie métabolique (MAFLD).

    Scheen, André J

    Revue medicale suisse

    2023  Volume 19, Issue 838, Page(s) 1498–1502

    Abstract: Metabolic-Associated Fatty Liver Disease (MAFLD) is a prevalent metabolic complication among patients with obesity and type 2 diabetes, associated with bad prognosis. Classical antidiabetics have little effects on this complication, except pioglitazone ... ...

    Title translation Effects of antidiabetic medications on metabolic-associated fatty liver disease.
    Abstract Metabolic-Associated Fatty Liver Disease (MAFLD) is a prevalent metabolic complication among patients with obesity and type 2 diabetes, associated with bad prognosis. Classical antidiabetics have little effects on this complication, except pioglitazone that exerts a positive impact but with uncertain safety. Gliptins are almost neutral, whereas glucagon-like peptide-1 receptor agonists showed benefits, the most potent ones being those associated with a greater weight loss such as liraglutide or semaglutide. Gliflozins also reduce hepatic fat content and liver enzymes used as biomarkers of steatosis. However, histological data remain scarce, especially those focusing on inflammation and fibrosis, and direct comparative data between available therapies are still lacking.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Non-alcoholic Fatty Liver Disease/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors ; Liraglutide/therapeutic use
    Chemical Substances Hypoglycemic Agents ; Dipeptidyl-Peptidase IV Inhibitors ; Liraglutide (839I73S42A)
    Language French
    Publishing date 2023-08-23
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.838.1498
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Gestion des médicaments antidiabétiques dans le décours d’une chirurgie bariatrique/métabolique.

    Scheen, André J

    Revue medicale suisse

    2023  Volume 19, Issue 838, Page(s) 1492–1495

    Abstract: The management of type 2 diabetes (T2D) after a gastric bypass or a sleeve gastrectomy requires some cautions depending on the timing after the surgical procedure and the patient evolution. Even before the intervention, gliflozins should be interrupted ... ...

    Title translation Use of antidiabetic medications in the course of bariatric/metabolic surgery.
    Abstract The management of type 2 diabetes (T2D) after a gastric bypass or a sleeve gastrectomy requires some cautions depending on the timing after the surgical procedure and the patient evolution. Even before the intervention, gliflozins should be interrupted to avoid euglycemic diabetic ketoacidosis while sulphonylureas should be stopped and insulin doses should be reduced (with caution) to limit the risk of hypoglycemia. If a remission of T2D occurs, the maintenance of metformin or of a glucagon-like peptide-1 receptor agonist should be considered with the main objective to prolong the remission. Finally, if T2D remains or if a relapse occurs, the management of hyperglycemia should a priori follow the same rules as those used for patients with T2D who are not treated with bariatric/metabolic surgery.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/therapeutic use ; Bariatric Surgery/adverse effects ; Metformin ; Sulfonylurea Compounds
    Chemical Substances Hypoglycemic Agents ; Metformin (9100L32L2N) ; Sulfonylurea Compounds
    Language French
    Publishing date 2023-08-23
    Publishing country Switzerland
    Document type English Abstract ; Journal Article
    ZDB-ID 2177010-4
    ISSN 1660-9379
    ISSN 1660-9379
    DOI 10.53738/REVMED.2023.19.838.1492
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5998: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?

    Scheen, André J

    Expert review of clinical pharmacology

    2023  Volume 16, Issue 11, Page(s) 1053–1062

    Abstract: Introduction: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice.: Areas covered: Both ... ...

    Abstract Introduction: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical practice.
    Areas covered: Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven their efficacy in reducing major cardiovascular events in high-risk patients with T2DM and SGLT2is in reducing hospitalization for HF in placebo-controlled randomized trials. However, real-life studies worldwide revealed that only a minority of patients with T2DM receive either a GLP-1RA or an SGLT2i and surprisingly even less patients with established ASCVD or HF are treated with these cardioprotective antihyperglycemic agents.
    Expert opinion: Bridging the gap between evidence-based cardiovascular protection with GLP-1RAs and SGLT2is and their underuse in daily clinical practice in patients with T2DM at high risk is crucial from a public health viewpoint. However, the task appears hazardous and the goal not attained considering the current failure. Education of specialists/primary care physicians and patients is critical. Multifaceted and coordinated interventions involving all actors (physicians, patients and broadly health-care system) must be implemented to stimulate the adoption of these cardioprotective antihyperglycemic medications as part of routine cardiovascular care among patients with T2DM.
    MeSH term(s) Humans ; Hypoglycemic Agents/adverse effects ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Cardiotonic Agents/pharmacology ; Heart Failure/drug therapy ; Atherosclerosis/complications ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/complications ; Glucagon-Like Peptide-1 Receptor/agonists
    Chemical Substances Hypoglycemic Agents ; Cardiotonic Agents ; Glucagon-Like Peptide-1 Receptor
    Language English
    Publishing date 2023-11-22
    Publishing country England
    Document type Journal Article
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2023.2279193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review.

    Scheen, André J

    Expert review of endocrinology & metabolism

    2023  Volume 18, Issue 4, Page(s) 271–282

    Abstract: Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of their glucose-lowering potency.: Areas covered: The ... ...

    Abstract Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of their glucose-lowering potency.
    Areas covered: The antihyperglycaemic potency of SGLT2is was compared with that of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, especially when added to metformin monotherapy. Main results of cardiovascular/renal outcome trials with SGLT2is were summarized in different populations: patients with type 2 diabetes mellitus (T2DM) with or without established cardiovascular disease, patients (with or without T2DM) with heart failure (with reduced or preserved left ventricular ejection fraction) and in patients (with or without T2DM) with chronic kidney disease (CKD, including stage 4). Original papers and meta-analyses of these different trials have consistently reported a reduction in hospitalization for heart failure (alone or combined with cardiovascular mortality) and a reduced progression of CKD, with an overall good safety profile.
    Expert opinion: Global use of SGLT2is has increased over time but remains suboptimal despite clinically relevant cardiovascular and renal protection, particularly in patients most likely to benefit. SGLT2is has proven both positive benefit-risk balance and cost-effectiveness in at risk patients. New prospects are expected in other complications, i.e. metabolic-associated fatty liver disease and neurodegenerative disorders.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Stroke Volume ; Ventricular Function, Left ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Heart Failure/drug therapy ; Glucose
    Chemical Substances Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2023-05-08
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1744-8417
    ISSN (online) 1744-8417
    DOI 10.1080/17446651.2023.2210673
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update.

    Scheen, André J

    Expert opinion on drug metabolism & toxicology

    2023  Volume 19, Issue 8, Page(s) 543–553

    Abstract: Introduction: Type 2 diabetes and liver disease, mainly metabolic-associated fatty liver disease (MAFLD) and more rarely cirrhosis, coexist in many patients. This duality has direct implications for the physician when choosing glucose-lowering agents, ... ...

    Abstract Introduction: Type 2 diabetes and liver disease, mainly metabolic-associated fatty liver disease (MAFLD) and more rarely cirrhosis, coexist in many patients. This duality has direct implications for the physician when choosing glucose-lowering agents, with classical concerns but also recent new hopes.
    Areas covered: This updated comprehensive review will consider the pharmacokinetics, the tolerance/safety profile, the benefit/risk balance in cirrhosis, the effects on MAFLD and the risk of hepatocellular carcinoma of old and new glucose-lowering compounds in patients with liver disease, with a special focus on glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors.
    Expert opinion: We are currently facing a new paradigm in the management of patients with diabetes and liver disease. From previous reluctance when using antidiabetic agents (except insulin) in diabetic patients with hepatic impairment because of safety concerns, the commercialization of novel glucose-lowering agents has changed the scene. These agents, which have a good safety profile, are associated with weight loss and pleiotropic effects. They have proven their efficacy in improving MAFLD. However, more specific studies are still needed to prove their efficacy in preventing the progression to fibrosis/cirrhosis and confirm this new opportunity for the management of patients with diabetes and liver disease.
    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/adverse effects ; Non-alcoholic Fatty Liver Disease/complications ; Non-alcoholic Fatty Liver Disease/drug therapy ; Insulin/therapeutic use ; Liver Cirrhosis/complications ; Liver Cirrhosis/drug therapy ; Glucose/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists
    Chemical Substances Hypoglycemic Agents ; Insulin ; Glucose (IY9XDZ35W2) ; Glucagon-Like Peptide-1 Receptor
    Language English
    Publishing date 2023-08-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2214462-6
    ISSN 1744-7607 ; 1742-5255
    ISSN (online) 1744-7607
    ISSN 1742-5255
    DOI 10.1080/17425255.2023.2252333
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6264: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top